Back

Clinical Chemistry

◐ Oxford University Press (OUP)

Preprints posted in the last 90 days, ranked by how well they match Clinical Chemistry's content profile, based on 22 papers previously published here. The average preprint has a 0.01% match score for this journal, so anything above that is already an above-average fit.

1
AI-Assisted Interpretation of Neurologic Autoantibody Cell-Based Assays

Qi, Z.; Cao, Z.; Tan, H.; Tang, B.; Shi, S. X.; Jia, R.; Yao, Y.; Chen, J.; Zhang, Z.; Wan, J.; Zheng, P.

2026-10-19 neurology 10.64898/2026.10.16.26365578 medRxiv
Top 0.1%
11.0%
Show abstract

Neurologic autoantibody cell-based assay images are difficult to interpret when fluorescence is weak, focal or dominated by background signal. We developed a visual artificial intelligence overlay that transfers detected cell boundaries from the structural channel to the antibody-staining image and evaluated standalone model concordance and its association with reader classifications. The analysis used 2 763 records for model development and 499 held-out records spanning 14 antibody targets. Four readers assessed the held-out records first without assistance and then with the boundary overlay and model category available. The selected model agreed with the reader-derived three-class reference in 85.2% of records, but recall was lowest for weak-positive or equivocal records. Reader agreement increased in the assisted session, and almost all revised ratings moved towards the model category. The combined display may support consistent visual review while also creating a risk of model-directed anchoring; its role as a second-read aid requires independent validation.

2
Optimization of a thermal shaker-aided quaking-induced conversion platform for the rapid detection of prion seeding activity in human samples

Miyazaki, Y.; Homma, T.; Nakagaki, T.; Takatsuki, H.; Mori, T.; Atarashi, R.; Satoh, K.; Ishibashi, D.

2026-09-16 neurology 10.64898/2026.09.10.26362572 medRxiv
Top 0.1%
7.0%
Show abstract

Creutzfeldt-Jakob disease (CJD) is a rapidly progressive, fatal neurodegenerative disorder caused by the misfolding of the normal prion protein (PrPC) into its pathogenic form (PrPSc). Therefore, effective clinical management and infection control require diagnostic assays that combine sub-attomole sensitivity with a turnaround time compatible with routine practice. While real-time quaking-induced conversion (RT-QuIC) offers excellent analytical performance, its protracted reaction time and dependence on plate readers that integrate high-speed shaking with continuous fluorescence detection restrict its widespread implementation. Endpoint QuIC (EP-QuIC) is an established alternative approach that utilizes vigorous shaking in a ThermoMixer(R) C and relies on a single endpoint fluorescence readout. In this study, we introduced minor modifications to assay conditions to enhance the speed, robustness, and reproducibility of EP-QuIC. The refined assay detected prion seeding activity in sporadic CJD brain samples within 6 h--and, in some cases, as early as 2 h. Unlike RT-QuIC, problematic recombinant PrP batches that impaired assay reliability in RT-QuIC--exhibiting delayed kinetics and spontaneous ThT fluorescence in unseeded reactions--did not produce such effects in EP-QuIC. Instead, they yielded strong, specific fluorescence signals that clearly identified sCJD samples, demonstrating improved batch tolerance and diagnostic efficiency of this approach. When applied to CSF, the EP-QuIC assay showed 100% sensitivity and specificity, highlighting its potential as a rapid, reliable diagnostic tool for prion diseases.

3
Differentiating benign from malignant adnexal masses by biomarker-agnostic plasma proteomics using adaptive machine learning

Mueller-Reif, J. B.; Ackroyd, S.; Albrecht, V.; Weigert, M.; Korff, K.; Schebesta, A.-S.; Yoeli-Bik, R.; Siddiqui, M.; Rausch, A.; Zsiros, E.; Mann, M.; Lengyel, E.

2026-09-25 obstetrics and gynecology 10.64898/2026.09.23.26363813 medRxiv
Top 0.1%
6.6%
Show abstract

Background: Pre-operative triage of adnexal masses with serum CA-125, HE4, and ultrasound (O-RADS) has limited accuracy, contributing to unnecessary surgery. We develop and validate a first of its kind, biomarker panel-free plasma proteomic classifier that distinguishes malignant from benign adnexal masses from a single blood draw, operating directly on discovery-mode mass spectrometry. Methods: In this multicenter prospective observational study, plasma from women with adnexal masses and from healthy controls at a large urban academic center (discovery and four validation cohorts) and an external academic center from another Urban-suburban area (external validation) was analyzed by data-independent-acquisition mass spectrometry (Orbitrap Astral), quantifying >1,000 proteins per sample. Cancerous (malignant, borderline adnexal mass, or metastasis to ovary) versus benign adnexal masses were classified with ADAPT-MS (Adaptive Diagnostic Architecture for Personalized Testing by Mass Spectrometry), which retrains an ElasticNet model for each sample based on the proteins measured. The primary outcome was discrimination (area under the receiver operating characteristic curve [AUC]). Pre-operative O-RADS scores and serum CA-125 were compared and combined with proteomics on matched subsets. Findings: Using a discovery cohort (n=1062), an ADAPT-MS classifier, validated across five independent cohorts (n=623), achieved a summary AUC of 0.835 (cohort range 0.779-0.904). Among patients with pre-operative O-RADS (n=231), proteomics (AUC 0.852) was comparable to O-RADS alone (0.863) and combining them raised discrimination to 0.922. Proteomics outperformed serum CA-125 (0.915 versus 0.777; n=125) and proteome-derived ROMA-like and two-marker surrogates. Biologically, the classification-relevant proteins are enriched for host response proteins rather than tumor cell associated protein changes, comprising ECM remodeling, complement and innate immune response pathways. This explains good detection of tumor with heterogenous pathology and also metastasis to ovary. Interpretation: A single plasma proteomic measurement interpreted using adaptive machine learning discriminates malignant from benign adnexal masses with good internal and external validation, and is complementary to ultrasound, warranting prospective evaluation as a panel-free diagnostic adjunct to imaging.

4
Preservation of intracellular protein-protein interactions in archived cytological specimens: Optimization of preanalytical variables for in situ proximity ligation assay

Dahlstrom, C. M.; Hirsch, J. M.; Lof, L.

2026-10-07 molecular biology 10.64898/2026.10.06.757074 medRxiv
Top 0.1%
6.5%
Show abstract

Context: Cytological specimens allow minimally invasive, repeated sampling for diagnosis and molecular testing. However, cytology biobanking protocols have primarily been optimized for morphology, and the effects of preanalytical handling and storage on intracellular proteins remain unclear. Objective: To assess how fixation, staining, storage temperature, and duration affect intracellular protein preservation in cytological specimens and to identify conditions suitable for in situ proximity ligation assay (isPLA). Design: Human cancer cell lines were processed under different preanalytical conditions. Intracellular proteins and protein protein interactions were assessed by isPLA, fluorescence microscopy, and quantitative image analysis. Slides were stored at room temperature or minus 20 Celsius, with or without MayGrunwaldGiemsa (MGG) staining. Results: Storage temperature had the greatest effect on protein signal. Unstained slides stored at minus 20 Celsius retained strong signals for up to 24 months, whereas room temperature storage reduced detectable protein interactions by approximately 95%. MGG staining further reduced signal intensity during prolonged storage. Nevertheless, stained slides remained suitable for isPLA when staining, microscopic evaluation, destaining, and antibody labeling were completed on the same day. Prolonged room temperature storage of stained slides caused loss of antigenicity, increased autofluorescence, and false negative findings. Conclusions: Low temperature storage and standardized preanalytical handling preserve intracellular protein signals in cytological specimens. These conditions support reliable single cell protein profiling of archived samples and their use in biomarker research and translational pathology.

5
Rapid Sepsis Diagnosis in Critically Ill Adults with Remoscope Label-Free Whole-Blood Imaging

Bratvold, N.; Jeyakumar, I.; Khoo, M.; Suematsu, G.; Chao, O.; Shwartzman, T.; Willmore, A.; Hutchinson, J.; Calfee, C.; Matthay, M.; Spottiswoode, N.; Langelier, C.; Lebel, P.

2026-10-11 intensive care and critical care medicine 10.64898/2026.10.08.26364716 medRxiv
Top 0.1%
4.4%
Show abstract

Sepsis is life-threatening, yet diagnosis remains a major global challenge because existing approaches lack speed and accuracy. Here we show that label-free imaging cytometry of 10 L whole-blood samples by Remoscope rapidly distinguishes patients with sepsis from those with non-infectious critical illness and healthy controls. In a prospective study of 29 critically ill adults, multi-physician adjudication identified sepsis (n=13), non-infectious critical illness (n=12), and indeterminate status (n=4); these patients were compared to healthy controls (n=22). A multiple instance learning (MIL) model pooled unbiased features from thousands of blood images per patient. Optimized for rule-out, the three-class model detected sepsis with 100% sensitivity and 85.3% specificity. Class activation heatmaps, unsupervised single cell embeddings, and morphometrics converged on abnormal leukocyte and erythrocyte morphology, including immature neutrophil-like cells. Label-free whole-blood imaging with MIL detects sepsis-associated hematologic signatures without stains or cold chain, establishing a foundation for rapid critical care diagnostics.

6
A Practical Assay for Assessing Mean Red Blood Cell Age Using the Protein 4.1a/4.1b Ratio

Makhro, A.; Seiler, E.; Bender, N.; Eppenberger, P.; Hobbs-Ray, C.; Baerlocher, G.

2026-10-09 biochemistry 10.64898/2026.10.08.757720 medRxiv
Top 0.1%
4.3%
Show abstract

BACKGROUND: The protein 4.1a/4.1b ratio is an intrinsic molecular marker of mean red blood cell (RBC) age resulting from progressive deamidation of protein 4.1b during RBC circulation. Despite its potential for estimating mean RBC age from a single blood sample, its application has been limited by labor-intensive RBC membrane preparation, and its interindividual variability has not been characterized in a large human population. METHODS: We developed a low-volume method for direct RBC membrane isolation from whole blood using saponin permeabilization and differential centrifugation without prior RBC washing. Membrane proteins were separated by SDS-PAGE, and protein 4.1a/4.1b ratios were determined by densitometric analysis with Gaussian peak fitting. Assay conditions, sample-volume requirements, membrane protein recovery, and analytical reproducibility were evaluated. The method was subsequently applied to 114 anonymized residual samples from routine diagnostic testing selected for complete blood count parameters within the corresponding laboratory reference intervals. RESULTS: The optimized procedure used 50 uL of whole blood, 0.06% saponin, and centrifugation at 9000 g, although protein 4.1a/4.1b remained measurable from starting volumes as low as 5 uL. Mean within-subject CVs were 3.90% for electrophoretic/densitometric determination and 5.39% for membrane protein recovery; whole-procedure CVs in 3 subjects were 1.40% to 3.50%. In the population analysis, the mean protein 4.1a/4.1b ratio was 1.428 (SD 0.146), with an observed range of 1.052 to1.799 and a central 95% interval of 1.151 to 1.695. Ratios did not differ significantly between females and males (P=0.246) or among females aged 18 to 50 years, females aged >50 years, and males (P=0.151). The ratio showed modest positive correlations with chronological age in females (Spearman p=0.26, P=0.047) and males (p=0.33, P=0.015), while substantial interindividual variability remained across the age range. CONCLUSIONS: Direct isolation of RBC membranes from small volumes of whole blood enables reproducible determination of the protein 4.1a/4.1b ratio using a simplified workflow. Application of the assay to a comparatively large human population revealed substantial interindividual variation in this molecular marker of mean RBC age that was not explained by sex or chronological age alone. The method provides a practical approach for investigating biological variation in mean RBC age and its potential contribution to laboratory measurements influenced by RBC survival.

7
From Routine Pathology to Precision Oncology: Automated FFPE Tissue Processing for Large-Scale Molecular Studies

Guedes, J.; Sliwa-Gonzalez, A.; Szadai, L.; Geiger, P.; Woldmar, N.; Reyes, M. A.; Bastida, R. A.; Coto, D. L. F.; Oskolas, H.; Marko-Varga, M.; Schultz, L.; Appelqvist, R.; Wieslander, E.; Malm, J.; Marko-Varga, G.; Gil, J.

2026-08-13 molecular biology 10.64898/2026.08.12.744404 medRxiv
Top 0.1%
4.3%
Show abstract

Melanoma incidence continues to rise globally, with formalin-fixed paraffin-embedded (FFPE) tissue archives representing an invaluable resource for large-scale retrospective proteomic studies. However, inconsistent deparaffinization remains a critical pre-analytical bottleneck limiting protein yield, reproducibility, and downstream data quality. In this study, we developed and validated a fully automated FFPE deparaffinization workflow using the Fluent(R) 780 liquid handling workstation (Tecan (C)) and evaluated its performance against a conventional manual protocol in a cohort of 54 patients with primary cutaneous melanoma, predominantly at early AJCC 8th edition stage I-II. The automated workflow achieved superior protein identification (6,146 {+/-} 860 vs. 4,941 {+/-} 1,091 proteins; p < 0.0001) with lower technical variability, while maintaining highly comparable global proteomic profiles as confirmed by principal component analysis and hierarchical clustering. A total of 8,305 proteins (96.1%) were identified by both methods, supporting the reproducibility and equivalence of the automated approach. Patients were stratified by the presence (N=21) or absence (N=33) of histological regression in the primary tumor. Proteomic comparison revealed 97 upregulated and 226 downregulated proteins in regressing melanomas, with pathway enrichment analysis demonstrating elevated mitochondrial and translational activity alongside reduced innate immune and complement pathway activation in the regression group. No statistically significant differences in overall, disease-free, or progression-free survival were observed between groups, consistent with the early-stage composition of the cohort. Digital pathology validated tissue morphology preservation across processing conditions. These findings support the integration of automated FFPE processing with proteomic and digital pathology workflows as a scalable platform for precision melanoma research. TOC Figure O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=133 SRC="FIGDIR/small/744404v1_ufig1.gif" ALT="Figure 1"> View larger version (49K): org.highwire.dtl.DTLVardef@1d51629org.highwire.dtl.DTLVardef@a1f126org.highwire.dtl.DTLVardef@1df1b0aorg.highwire.dtl.DTLVardef@686f1c_HPS_FORMAT_FIGEXP M_FIG C_FIG

8
Matched marrow and blood profiling reveals compartment- and feature-specific liquid-biopsy signals in multiple myeloma

Abelman, D. D.; Eagles, J.; Pedersen, S.; Scott, D. S.; Danesh, A.; Bruce, J. P.; Prokopec, S. D.; Wong, A.; Wei, E. N.; Shah, S.; White, D.; Sandhu, I.; Song, K.; Murugesan, A.; Reiman, A.; Trudel, S.; Pugh, T. J.

2026-09-14 oncology 10.64898/2026.09.09.26358882 medRxiv
Top 0.1%
4.0%
Show abstract

Multiple myeloma is bone-marrow-predominant, motivating marrow plasma cell-free DNA (cfDNA) as a tumor-proximal liquid biopsy. We tested whether marrow plasma cfDNA better represents the myeloma genome than peripheral blood cfDNA by profiling matched marrow plasma cells and both cfDNA compartments from 74 patients across 372 cfDNA sample time points. Tumor fractions correlated between compartments (r=0.84), but marrow plasma cfDNA was not a superior surrogate: peripheral-blood cfDNA matched or exceeded marrow-plasma cfDNA for marrow-defined CNA and mutation recovery (77.4% vs 72.0%; 69.2% vs 65.4%), with high specificity. Disease-associated features were detected in 69/74 peripheral-blood and 68/74 marrow-plasma profiles. BCR clonotypes were the highest-recovery feature, with BM-dominant clonotypes recovered in 31/34 callable profiles per compartment. At high tumor fraction, adverse-lesion sensitivity reached 100% in both cfDNA compartments. Marrow plasma cfDNA showed distinct, handling-sensitive fragmentomic architecture (LOOCV AUC=0.910), demonstrating performance depends on compartment, biomarker class, tumor fraction and processing context.

9
Quantifying Blood Culture Volume Using an Automated System: Insights from Pediatric and Adult Simulated Collections Using BACTEC FXI

Turner, D.; Herr, J.

2026-08-25 infectious diseases 10.64898/2026.08.21.26361057 medRxiv
Top 0.1%
4.0%
Show abstract

Objectives: Capturing adequate blood volume for blood cultures is critical for accurate detection of bloodstream infections. Pediatric volume targets vary by age and weight, whereas adult targets are standardized. The BD BACTEC FXI Culture System (FXI) contains an integrated calibrated load cell capable of automatically reporting blood volume measurements for each vial loaded onto the system. This study evaluated the accuracy of the FXI's blood volume measurements in simulated pediatric and adult patients. Methods: Mock pediatric and adult blood draws were performed, using bagged whole blood, to replicate real-world collection protocols. Syringe-collected blood volumes ranged from 2.0 to 15.0 mL for pediatric patients, depending on mock patient weight, and were fixed at 40.0 mL for adults. Samples were inoculated into BD BACTEC Peds Plus/F, Plus Aerobic/F, and Lytic/10 Anaerobic/F Culture Vials, with a target volume of 2.0 to 10.0 mL per bottle. Reference blood volumes were determined gravimetrically using manually obtained pre- and post-inoculation weights with a blood-specific gravity of 1.055 g/mL and were compared to the automatically measured, gravimetric-based blood volumes reported by the BACTEC FXI Culture System. Results: Automated volume estimates were accurate to a mean error of -0.03 mL per bottle (SD, 0.40 mL; n=168; 95% CI, -0.09 mL, 0.03 mL) and -0.08 mL (SD, 0.79 mL; n=72; 95% CI, -0.26 mL, 0.10 mL) when assessing total volume collected per patient. Conclusions: Our findings demonstrate that the automated system can quantify blood volumes in BACTEC culture vials and support blood volume monitoring for pediatric and adult collections. The gravimetric approach is also amenable to full automation for efficient and accurate blood volume determination.

10
AI-Assisted Tissue-Based Antibody Interpretation in Autoimmune Encephalitis: Prospective Validation and Reader Study

Cao, Z.; Xie, D.; Zou, S.; Li, D.; Martinez-Martinez, P.; Zong, S.; Zhang, Z.

2026-10-11 neurology 10.64898/2026.10.08.26365042 medRxiv
Top 0.1%
3.6%
Show abstract

Tissue-based assays provide broad screening for neural autoantibodies but remain vulnerable to technical and reader-dependent variability. We evaluated an integrated workflow combining automated 3,3'-diaminobenzidine tissue-based assay processing, digital whole-slide imaging, and interpretable deep learning. Model development used 2,357 retrospective serum and cerebrospinal fluid images referred from more than 80 institutions and processed in a centralized laboratory, with reference labels established by expert-consensus tissue-based assay interpretation. A prospective validation cohort included 200 images from 200 unique patients (154 positive and 46 negative; 100 serum and 100 cerebrospinal fluid). The same images were evaluated by two expert and two novice readers in a fixed-order two-round study, with unaided interpretation followed by artificial-intelligence-assisted interpretation after a washout of at least two weeks. The standalone binary classifier achieved an area under the receiver operating characteristic curve of 0.922, accuracy of 86.5%, sensitivity of 85.7%, and specificity of 89.1% in prospective validation. Pooled reader accuracy was 90.4% in the unaided round and 97.4% in the artificial-intelligence-assisted round (McNemar P < 0.001), with specificity of 82.6% and 99.5%, respectively. Novice-reader accuracy was 83.3% unaided and 96.5% with artificial-intelligence assistance (P < 0.001), approaching unaided expert accuracy of 97.5%. Among tissue-based-assay-positive cases, reader accuracy for cytoplasmic/nuclear antigen-associated versus neural surface antigen-associated staining-pattern subclassification was 88.8% unaided and 94.0% with artificial-intelligence assistance (P < 0.001). These findings support further multicentre, cross-platform evaluation of artificial-intelligence-assisted neural autoantibody tissue interpretation.

11
Proximity Labeling-Assisted Flow Cytometry Improves Fluorescence Contrast in Extracellular Vesicle-Enriched Fractions

Kashimata, L.; Iwasa, K.; Kumagai, M.; Sasaki, R.; Shinomiya, S.; Soma, M.; Iemura, H.; Sekiya, R.; Horiuchi, I.; Katsuki, M.; Komatsu, K.; Mizuno, Y.; Nakamura, H.; Nagata, M.; Sato, T.; Ito, K.; Kawasaki, Y.; Nakagome, K.; Kotani, N.

2026-09-17 biochemistry 10.64898/2026.09.15.751677 medRxiv
Top 0.1%
3.4%
Show abstract

Extracellular vesicles (EVs) are potential sources of circulating biomarkers, but disease-associated EVs are often scarce and their nanoscale dimensions limit analysis by conventional flow cytometry. To improve the detection of disease-associated EV signals using widely available instruments, we developed a workflow combining preparation of serum EV-enriched fractions by size-exclusion chromatography, CHL1-initiated enzyme-mediated activation of radical sources (EMARS) proximity labeling, and conventional flow cytometry. EMARS deposits fluorescein on molecules proximal to antibody-bound CHL1, thereby increasing target-initiated fluorescence. In a representative comparison, EMARS increased the signal-to-background ratio from 1.21 with conventional antibody labeling to 6.28. Because unlabeled EVs and debris interfered with analysis, we used an AI-assisted procedure to explore FITC-H cutoffs for retained P1 events. ChatGPT compared 65 candidate cutoffs across statistical and event-retention metrics and recommended 1000; the authors reviewed the complete results before adopting this value. At this data-selected cutoff, mean fluorescence intensity was higher in interstitial lung disease (ILD) than in non-ILD samples among 28 evaluable samples (P = 0.002; area under the receiver operating characteristic curve [AUC] = 0.846); neither value was adjusted for cutoff selection. Post hoc nested leave-oneout cross-validation (LOOCV), in which cutoff selection was repeated within each outer fold, yielded an AUC of 0.716 with 29 of 34 samples evaluable. The association with ILD requires validation in independent cohorts, but these exploratory findings suggest that proximity labeling may enhance measurable fluorescence contrast in serum EV-enriched fractions and support further evaluation of disease-associated EV signals using conventional flow cytometers.

12
Host gene-expression signatures accurately distinguish bacterial, viral, and inflammatory diseases in febrile children across multiple cohorts

Viz-Lasheras, S.; Dacosta, A.; Rivero-Calle, I.; Martinon-Torres, F.; EUCLIDS, GENDRES, PERFORM, and DIAMONDS consortia, ; Gomez-Carballa, A.; Salas, A.

2026-08-18 genomics 10.64898/2026.08.11.744042 medRxiv
Top 0.1%
3.3%
Show abstract

Accurate discrimination between viral, bacterial, and inflammatory diseases in febrile children remains a major clinical challenge that contributes to diagnostic uncertainty, inappropriate antimicrobial use, and suboptimal clinical management. Host blood transcriptomics offer a promising strategy to improve diagnostic precision. The present study represents the largest integrative multi-cohort pediatric study of transcriptomic biomarker discovery, validation, and confirmation reported to date, integrating harmonized public transcriptomic datasets with an independent confirmation cohort comprising well-phenotyped patients to identify parsimonious host-response signatures for differentiating viral, bacterial, and inflammatory diseases. Transcriptomic signatures were derived from an integrated retrospective microarray multi-cohort (n=1,683), independently validated in a retrospective RNA-seq cohort (n=767), and confirmed by digital PCR in an independent cohort (n=29), demonstrating reproducibility across patient populations, transcriptomic technologies, and analytical platforms. The analysis identified binary signatures and a unified multiclass classifier that consistently achieved high diagnostic accuracy across all three study phases and outperformed more than 30 published host transcriptomic signatures. Decision curve analysis showed substantially greater clinical net benefit than C-reactive protein across clinically relevant decision thresholds. These findings provide a strong foundation for clinically deployable molecular diagnostics to improve patient triage, antimicrobial stewardship, and precision medicine in childhood infections.

13
Whole Blood Deep Immunophenotyping and Platelet-Leukocyte Aggregate Quantification by Spectral Flow Cytometry

Ding, H.; Gerbino, K. R.; Gilham, K.; Tong, Y.; Hu, A.; Huang, E. L.; Zabriskie, E.; Ozpolat, T.; Guo, L.; Brakenridge, S. C.

2026-10-07 immunology 10.64898/2026.09.30.755388 medRxiv
Top 0.1%
2.8%
Show abstract

Platelet-leukocyte aggregates (PLAs) are a proposed interface between coagulation and immune regulation, but their distribution across leukocyte subsets beyond monocytes and neutrophils, and their behavior in acute disorders of immune regulation, such as sepsis and severe trauma, remain largely undefined. The study of thromboimmune mechanisms in these acute conditions has relied heavily on murine sepsis models, whose species differences in platelet and leukocyte biology limit translation to human disease. Direct measurement in human whole blood is needed yet reported PLA frequencies vary widely because quantification is highly sensitive to sample handling. Here we present a robust, minimally manipulative 27-color spectral flow cytometry protocol that allows simultaneous deep immunophenotyping and classification of PLAs across >40 leukocyte subpopulations. In healthy donors, PLA frequency ranged from 1.7% on memory CD4 T cells to over 50% on monocyte subsets, with monocytes contributing 25% of all PLAs. We also found novel platelet-binding leukocyte populations, including Th9 and Th22 CD4+ T cells. Optimization identified anticoagulant choice, centrifugation conditions, dilution, and sample processing time as key determinants of reproducible measurement; PLA quantification was validated by imaging flow cytometry. In a small validation cohort of sepsis and trauma patients, the assay recapitulated established immunophenotypic features of critical illness, including neutrophilia and myeloid-derived suppressor cells (MDSC) expansion, and quantified PLAs within each subset. This protocol provides a reference framework for studying thromboinflammation and other dysregulated immune response diseases directly in human blood, and a foundation for further studies, defining the mechanisms and clinical relevance of platelet-leukocyte interactions in disease.

14
Rapid Molecular Assessment of Kidney Allograft Rejection Using the Biopsy Transport Medium

Li, Z.; Kalverboer, N.; van der Helm, D.; Callegaro, G.; van de Water, B.; Meziyerh, S.; Vries, A. P. J. d.; Baelde, H. J.; Kers, J.

2026-10-02 neurology 10.64898/2026.10.01.26364480 medRxiv
Top 0.1%
2.7%
Show abstract

Introduction Timely diagnosis of kidney allograft rejection is critical for post-transplant management, yet treatment decisions may need to be made empirically while awaiting the final pathology report. We previously demonstrated that biopsy transport medium (BTM) contains molecular signals reflective of allograft rejection. Building on these findings, we developed a rapid BTM qPCR workflow using a targeted gene panel for early molecular assessment of rejection. Methods Kidney transplant biopsies assessed at Leiden University Medical Center from April 2023 to November 2024 were eligible. A predefined gene panel was quantified in BTM by qPCR, while matched formalin-fixed paraffin-embedded tissues were profiled using Tempo-Seq. Elastic Net, Random Forest, and support vector machine models were developed to classify rejection and predict continuous histological indices directly from the BTM. Results A total of 134 paired BTM samples and biopsy tissues were analyzed. The best-performing BTM gene-panel models demonstrated good discrimination for rejection, with a median AUC of 0.80, and good calibration (median slope, 0.92; median intercept, 0.08). For continuous histological indices, the best-performing BTM gene-panel models achieved R square values of 0.33 for Activity, 0.31 for TCMR/TI, and 0.27 for AMR/MVI. Corresponding biopsy gene-panel models showed similar patterns across diagnostic outcomes. Conclusions The BTM qPCR workflow captures molecular features of kidney allograft rejection and enables prediction of rejection status along the spectrum of continuous activity indices. By providing same-day molecular information while definitive biopsy interpretation is pending, this rapid approach has the potential to complement conventional histopathological diagnostics and support early clinical decision-making.

15
Pitfalls in understanding PhIP-Seq data: technical variability, replicability, and best practices for interpretation

Trgovec-Greif, L.; Vogl, T.

2026-09-21 bioinformatics 10.64898/2026.09.15.751724 medRxiv
Top 0.1%
2.5%
Show abstract

Phage Display Immunoprecipitation sequencing (PhIP-Seq) is a high throughput method allowing to measure antibody binding against hundreds of thousands of potential antigens. Typically, blood samples of hundreds to thousands of individuals are measured in 96-well plates, necessitating distribution of samples on multiple plates and processing in batches. To correctly interpret PhIP-Seq results, it is crucial to understand its nature and technical limitations. Here, we analyzed 195 technical replicates of controls (anchor samples) from 49 plates measured in 13 immunoprecipitation runs to gauge technical variability and replicability. While there were few false-positive enriched peptides, we observed a substantial fraction of false negatives. The total number of enriched peptides can be affected by batch effects. Additionally, the type of biological material used (serum or plasma) influences enrichment profiles with an antigen library containing bacterial proteins due to the interaction of phages with plasma proteins. Finally, replicating measurements in different labs produces comparable enrichment profiles, but slight differences in a subset of peptides are noticeable. These results suggest best practices for PhIP-Seq experiments. Most importantly, due to batch effects, samples of cases and controls should be evenly distributed between 96-well plates to avoid confounding with biological effects. Also, for highly complex libraries, the total number of enriched peptides can be a technical artifact and potentially not a feature useful in comparisons.

16
Mutanome-guided immunopeptidomics of blood plasma for neoepitope detection in solid tumors is constrained by cfDNA variant calling sensitivity and MS detection limits

Kienzle, A.; Becker, J. P.; Fendl, B.; Tomasich, E.; Heller, G.; Wellach, K.; Samimi, K.; Eiz-Vesper, B.; Starzer, A. M.; Berger, J. M.; Sunder-Plassmann, V.; Kiesel, B.; Bock, C.; Widhalm, G.; Preusser, M.; Berghoff, A. S.; Riemer, A. B.

2026-09-26 immunology 10.64898/2026.09.21.753080 medRxiv
Top 0.1%
1.9%
Show abstract

Introduction: Neoepitopes form the basis of tumor-specific immune responses. Tissue biopsy, the primary source for neoepitope detection, is limited and invasive. Therefore, we aimed to identify neoepitopes by mutanome-guided immunopeptidomics from plasma of cancer patients. Methods: Mass spectrometry (MS) data analysis of HLA ligands from plasma (n = 4) was guided by patient-specific mutanomes of cell-free DNA (cfDNA) from plasma or tumor genomic DNA (tgDNA) from tissue. Matched tumor tissue and healthy donor plasma served as controls. Neoepitopes were validated with synthetic peptides, and immunogenicity was assessed using IFN-gamma ELISpot and intracellular cytokine staining. Results: Wild-type immunopeptidomes from tissue and plasma overlapped by 58%, with 91% of plasma HLA ligands rediscovered in tissue. 13 out of 15 tumor-associated HLA ligands detected in plasma were rediscovered in the matching tissue. However, no neoepitopes in plasma were identified by immunopeptidomics guided by cfDNA mutanomes, likely reflecting the limited overlap between cfDNA and tgDNA mutanomes (15%). Using the tgDNA mutanome as a complementary reference, two neoepitopes were detected in one patient's plasma, albeit at the MS detection limit. Both neoepitopes were also discovered in tissue, along with three tissue-exclusive neoepitopes. Two tissue-exclusive neoepitopes induced antigen-specific T cell responses in healthy donor PBMCs. Conclusion: In summary, plasma immunopeptidomics enables profiling of HLA ligands from wild-type proteins, including TAAs. In principle, neoepitope detection from plasma at the peptide level is feasible, but tissue remains the gold standard for variant calling and neoepitope identification. Improved detection methods may enable minimally invasive approaches in the future.

17
Comprehensive characterization of genomic, transcriptomic and epigenomic artifacts introduced in formalin-fixed, paraffin-embedded tissues.

Zmuda, E. J.; Covington, K. R.; Kandoth, C.; Ng, C. K. Y.; Weisenberger, D. J.; Bowlby, R.; Chu, A.; Corbett, R.; Brooks, D.; Cherniack, A. D.; Murray, B.; Ling, S.; Zhao, W.; Shinbrot, E.; Lim, R. S.; Bootwalla, M. S.; Hinoue, T.; Hu, J.; Kakkar, N.; Lawrence, M.; McLellan, M.; Miller, C.; Morton, D.; Mungall, A. J.; Muzny, D.; Sougnez, C.; Stojanov, P.; Xi, L.; Schultz, N.; Akbani, R.; Curtis, C.; Fulton, B.; Gibbs, R. A.; Getz, G.; Spellman, P.; Marra, M.; Ladanyi, M.; Tarnuzzer, R.; Sofia, H.; The Cancer Genome Atlas Research Network, ; Hutter, C.; Wheeler, D. A.; Gastier-Foster, J.; Lair

2026-09-03 bioinformatics 10.64898/2026.08.31.748145 medRxiv
Top 0.1%
1.8%
Show abstract

Genomic, transcriptomic and epigenomic characterization has accelerated the discovery of clinically-relevant alterations in cancer, predominantly using fresh frozen (FF) specimens. However, clinical molecular pathology laboratories prefer formalin-fixed paraffin-embedded (FFPE) methods, known to introduce artifacts at the nucleic acid level, over fresh frozen methods. Extending the multi-platform analysis to FFPE specimens for comprehensive clinical molecular diagnosis requires a thorough understanding of the consequence of formalin-fixation. We present a detailed multi-platform characterization of FFPE preservation using paired FF specimens as the 'gold standard'. DNA and RNA were obtained from 38 patients across 6 cancer types using a FFPE optimized co-isolation. The impact of FFPE on exome sequencing was dependent on filtering, where a minimum coverage or supporting read filter can mitigate FFPE-specific false positives. Copy number alterations, MSI assessment, mutational signatures, and DNA methylation were comparable between FFPE and FF. FFPE biases in RNA expression can be overcome when using biology-relevant genes and we describe a novel consequence of FFPE on miRNA species diversity. Collectively, this data provides a broad view of FFPE artifact and offers best practices for overcome these biases.

18
Serial Immunohistochemistry for High-Dimensional Single-Cell Spatial Analysis of Human Kidney Biopsies

Yang, X.; Marlin, M. C.; Celia, A. I.; Lee, C.-Y.; Cammarata-Mouchtouris, A.; Stephens, T.; Haddad, M.; Bradshaw, L.; Saksena, D.; Buyon, J.; Izmirly, P. M.; Putterman, C.; Kamen, D.; Petri, M.; Accelerating Medicines Partnership: RA/SLE Network, ; James, J. A.; Guthridge, J. M.; Fava, A.; Rosenberg, A. Z.

2026-08-12 pathology 10.64898/2026.08.06.743188 medRxiv
Top 0.1%
1.5%
Show abstract

BackgroundTraditional immunohistochemistry (IHC) with chromogen detection has limited multiplex capacity, detecting at most 4 protein markers per tissue section simultaneously, thereby restricting comprehensive spatial analysis of valuable human biopsies. We developed and validated a robust serial IHC (sIHC) staining method to detect multiple antigens on a single kidney biopsy slide, maximizing data yield for diagnosing and studying complex kidney diseases. MethodsFormalin-fixed, paraffin-embedded kidney biopsy sections were subjected to repeated IHC/imaging cycles with antibody removal using an optimized sodium dodecyl sulfate-glycerol buffer stripping protocol. Images were then co-registered, and analysis was performed using a variety of methodologies, including color deconvolution, cell segmentation, and spatial clustering. ResultsThis optimized sIHC method successfully detected up to 20 antigens on a single slide. Combining image analysis and artificial intelligence software, for example with HALO (Indica Labs), the assay assembles high-dimensional images and enables quantitative histology and single-cell spatial analysis. Using this advanced method, we were able to identify rare cell populations, such as double-negative T cells, that are challenging to detect conventionally. ConclusionWe have developed a validated, high-capacity sIHC protocol that uses standard IHC procedures with commercially available, clinically validated off-the-shelf antibodies. This method is a valuable, cost-effective tool for obtaining extensive, high-dimensional single-cell-resolved spatial data from limited pathology samples, such as a human kidney biopsy.

19
Benchmarking fragmentation-derived artificial cfDNA reference standards

Cornelli, L.; Nhat Nguyen, T.; Van Belle, R.; Roelandt, S.; De Cock, A.; Van der Meulen, J.; Loontiens, S.; Van Roy, N.; De Preter, K.

2026-08-21 genomics 10.64898/2026.08.12.744389 medRxiv
Top 0.1%
1.5%
Show abstract

An important step toward clinical implementation of (epi-)genomic assays on liquid biopsies is their validation on identical samples within and across laboratories. For these validation studies, there is a need for cell-free DNA (cfDNA) samples with defined tumor fractions and (epi-)genomic aberrations. However, the amount of circulating cfDNA isolated from patient samples is often limited, especially in pediatric cases. Additionally, patient samples contain a high degree of variability in cfDNA yield and tumor fraction. Several commercial artificial cfDNA products are available for validation studies, however their use is restricted to specific assays, aberrations and/or tumor entities. Alternatively, artificial cfDNA samples can be produced by fragmenting genomic DNA to mimic highly fragmented cfDNA derived from both tumor and healthy blood, followed by mixing artificial tumoral and healthy cfDNA at defined fractions. In this study, we compared native cfDNA with artificial cfDNA generated by three different fragmentation methods, including sonication and two enzymatic digestions using micrococcal nuclease and double-stranded deoxyribonuclease (dsDNase). We assessed fragment length profiles, end motifs and nucleosome occupancy patterns from shallow whole-genome sequencing data, as well as coverage profiles from targeted panel sequencing, together with a small-scale mixing experiment of tumor and healthy cell derived artificial cfDNA. Although sonication remains a convenient high-throughput approach to generate artificial cfDNA for certain downstream applications, enzymatic fragmentation, particularly the dsDNase-based method, more faithfully reproduced native cfDNA characteristics.

20
Recombinase polymerase amplification: characterization and mitigation of undescribed multimeric artefacts

De Keyzer, L.; Deserranno, K.; Skevin, S.; Van Hoofstat, D.; Deforce, D.; Van Nieuwerburgh, F.

2026-08-21 biochemistry 10.64898/2026.08.21.741777 medRxiv
Top 0.2%
1.5%
Show abstract

Recombinase polymerase amplification (RPA) enables rapid nucleic acid testing in low-resource environments, but poorly characterized byproducts can compromise assay specificity and cause false-positive results. Here, we amplified the thirteen original CODIS core loci and Amelogenin to characterize recurrent RPA artefacts and establish conditions that reduce their formation. First, RPA products were analyzed for two reference samples by Oxford Nanopore Technologies sequencing. This revealed two distinct classes of multimeric products: primer multimers and amplicon multimers, consisting of repeated primer or amplicon sequences, respectively. Individual artefacts contained up to 281 primer copies or 22 amplicon copies, demonstrating the extensive range of these products. Next, we performed an optimization study to evaluate the effects of reaction temperature and reagent concentrations at two representative loci, D3S1358 and D5S818. Among the conditions tested, temperature had the most pronounced effect. Reducing the temperature from 42{degrees}C to 34{degrees}C increased the relative target amplicon fraction from 15% to 83% for D3S1358 and from 84% to 98% for D5S818, while maintaining or increasing absolute target concentration. Lower primer concentrations and higher T4 UvsX concentrations also reduced multimer formation, although lower primer concentrations reduced target yield and caused allelic dropout. Finally, amplification at 34{degrees}C was evaluated across all fourteen loci by sequencing. Relative to 42{degrees}C, the target read fraction increased by more than 5 percentage points for 7/14 loci in one reference sample and 9/14 loci in the other, with the largest improvements at multimer-prone loci. These findings identify multimers as an important class of RPA artefacts and establish reaction temperature and T4 UvsX concentration as promising conditions to improve RPA specificity.